Abstract: FR-PO253
Multiple Cancers Alters Renal Physiology and Induces Kidney Injury and Inflammation
Session Information
- Onconephrology: From AKI to CKD and Everything in Between
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Onconephrology
- 1700 Onconephrology
Authors
- Hammouri, Dana, University of Louisville, Louisville, Kentucky, United States
- Siskind, Leah J., University of Louisville, Louisville, Kentucky, United States
Background
The altered physiology of cancer patients and their unique susceptibility to kidney disease has led to the rapidly growing specialty of Onconephrology. Cancer patients often have decreased kidney function, and drug-induced acute kidney injury (AKI) is common and remains a hurdle. Drug-induced AKI can interrupt therapy and reduce overall survival. Our lab has recently shown that lung-cancer enhances the nephrotoxicity of cisplatin. Additionally, we were able to show that lung-cancer alone alters kidney physiology. However, we are unaware if this phenomenon is exclusive to the model we tested. In this study we used multiple cancer types to determine if kidney function, injury, and inflammation are being altered by subcutaneous cancer alone.
Methods
Eight- to ten-week-old B6;129 mice were randomly assigned into six group of non-cancer and various other cancer types. In the cancer groups, cancer cells were injected subcutaneously and followed for tumor size. Animals were euthanized once tumor size met necessary endpoint per IACUC protocol.
Results
Different cancer types have varying effects on altering kidney function, injury and inflammation. Metastatic lung cancer induces the largest changes, compared to non-metastatic lung cancer. Additionally, melanoma increased urinary NGAL, but did not increase KIM-1 expression.
Conclusion
The presence of subcutaneous tumors is sufficient to alter kidney biology, induces renal injury and inflammation and reduce renal function. Further studies will need to be conducted to elucidate the mechanism behind these changes. Understanding the tumor-kidney crosstalk may provide mechanistic insights and uncover novel therapeutic targets for onconephrology patients.
Funding
- NIDDK Support